BetaEntity Annotation Prototype
← Back to diseases

Annotated abstract

Optimising adalimumab administration to improve patient experience and treatment adherence in immune-mediated inflammatory diseases

ejhpharm · 2025-10-24 · canonical JSON source

2 visible annotations · policy: published · automated confidence ≥ 75.00%

Document resource

Immune-mediated inflammatory diseases (IMIDs) are a group of pathologies characterised by acute or chronic inflammation that can affect a multitude of organs such as the skin, joints or digestive tract.1 Their prevalence in Western society is between 5% and 7%.2